PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors
Phase I Trial of BMN 673 and Selected Cytotoxics in Patients With Advanced Solid Tumors
Sponsor: BioMarin Pharmaceutical
Listed as NCT02049593, this PHASE1 trial focuses on Metastatic Cancer and Unspecified Adult Solid Tumor and remains completed. Sponsored by BioMarin Pharmaceutical, it has been updated 11 times since 2014, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Sep 2022 — Jul 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Sep 2022 [monthly]
Completed PHASE1
-
Dec 2019 — Jan 2021 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
▶ Show 6 earlier versions
-
Sep 2019 — Dec 2019 [monthly]
Active Not Recruiting PHASE1
-
Aug 2018 — Sep 2019 [monthly]
Active Not Recruiting PHASE1
-
Jul 2018 — Aug 2018 [monthly]
Active Not Recruiting PHASE1
-
Jun 2018 — Jul 2018 [monthly]
Active Not Recruiting PHASE1
-
Feb 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE1
First recorded
Jun 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- BioMarin Pharmaceutical
- Jonsson Comprehensive Cancer Center
- Medivation, Inc.
- Translational Research in Oncology
For direct contact, visit the study record on ClinicalTrials.gov .